Perfil de la empresa para ULTIMOVACS AS DK1 Acción
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Obtén información actualizada de finAgent sobre ULTIMOVACS AS DK1